Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Finding Phase I Followed by a Phase II Study to Evaluate the Safety and Efficacy of Allogeneic NK-cell Combined With Chemotherapy in Patients With PDA or Cholangiocarcinoma After Surgery

NCT06730009 is registered in ClinicalTrials.gov with Medigen Biotechnology Corporation as lead sponsor.

NCT NCT06730009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06730009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Finding Phase I Followed by a Phase II Study to Evaluate the Safety and Efficacy of Allogeneic NK-cell Combined With Chemotherapy in Patients With PDA or Cholangiocarcinoma After Surgery
Lead sponsor
Medigen Biotechnology Corporation
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 21, 2024
Completion date
August 31, 2029
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma resectable, pancreatic carcinoma stage ii